For the last two decades the medical management of Parkinson's disease (IPD) has been based largely on the use of oral preparations containing levodopa. This period has been more than ample to witness the continuing progression of the underlying disease, and the myriad complications of the long-term levodopa syndrome. Recently, the medical approach has been expanded to incorporate three distinct, but inter-related, arms. First, the possibility that certain treatments might prevent, retard or halt the underlying pathological process. Second, the ability of symptomatic treatment using new drugs, or old drugs with new strategies or delivery systems, to limit the appearance, or lessen the impact, of response fluctuations. Finally, the prospect of restorative treatment using cell implants. This editorial will concern itself with the first two aspects.
The cause of IPD is unknown. However, a clinically identical syndrome (although pathologically lacking classical Lewy bodies) can be induced in humans, and a similar syndrome in other primates, by the protoxin MPTP. Pretreatment with MAO B inhibitors such as selegiline (deprenyl) prevents MPTP-induced parkinsonism in primates' by blocking its conversion in glia or nondopaminergic neurons through the intermediate MPDP+ to the toxic moiety MPP+. Dopamine reuptake blockers such as mazindol, nomifensine and benztropine can also protect by inhibiting the uptake of MPP+ into dopaminergic neurons. Once within these cells, MPP+ is actively accumulated in mitochondria, where it disrupts energy metabolism somewhere between NADH dehydrogenase and coenzyme Q10.2 A redox reaction between MPDP+ and MPP+, also blocked by selegiline, may also generate free radicals through the formation of superoxide. 3 In IPD substantia nigra, recent studies have demonstrated impaired function of complex 1 of the mitochondrial respiratory chain.4 In this structure, there is also evidence of an increase in total iron concentration (in the absence of a "neutralising" increase in ferritin)5 and of enhanced lipid peroxidation,6 which could be respectively a mediator and a result of free radical attack. The onward metabolism of dopamine itself may also increase oxidative stress. Thus, regardless of whatever initiates the process of nigrostriatal neuronal death, the increased dopamine turnover of surviving cells, and its further acceleration when exogenous levodopa is administered, might cause these neurons to "self-destruct". The use of an MAO B inhibitor, or of a direct dopamine agonist which would diminish presynaptic dopamine turnover, could theoretically limit this process. For example in haloperidol-treated rats selegiline suppresses the rise in glutathione disulfide which occurs as a result of increased dopamine turnover. 7 Accepting all the uncertainty of the quantum leaps from MPTP parkinsonism to IPD, and from rats through lower primates to humans, the stage is therefore set for studies of the disease-modifying potential of MAO B inhibition, and of anti-oxidant therapies such as alpha-tocopherol retrospective study claiming increased life expectancy in 564 patients receiving Madopar plus selegiline, compared to 377 patients treated with Madopar alone. This study was completed before anything was known of the ability of selegiline to protect against MPTP toxicity in primates. Of the many confounding variables, the significantly higher mean dose of Madopar in the selegiline group was particularly unsettling.
Selegiline does not usually exert a significant symptomatic effect when given alone to patients with Parkinson's disease. However, such monotherapy has only been used in a few patients, and at least one open study'2 has demonstrated significant improvement on the Webster score at both three and six months in a group of 30 patients. The metabolism of selegiline produces small amounts of amphetamine and methamphetamine and, whether due to this or other effects, the drug has been claimed to be "the best drive-boosting antidepressant available",'3 although many would question the evidence for this.
The results of two randomised double-blind prospective studies of selegiline versus placebo in otherwise untreated subjects with early PD have recently been published.'4 '"
The end-point for individual patients in each study was when, in the judgement of the investigator, a subject reached a level of functional disability sufficient to warrant the initiation of levodopa therapy, or when the subjects had completed three'4 16 years of treatment without needing levodopa. In both studies, a washout period of one month was observed after end-point and before starting levodopa in the hope that any "symptomatic" effect of selegiline might thereby be detected (although PET studies"7 have shown that partial inhibition of MAO B due to selegiline is still present at least three weeks after the last dose). As well as semi-objective PD rating scales, scales for depression were also administered.
The results of each study were broadly similar: both used 10mg selegiline daily. The California study'4 did not detect significant overall clinical improvement on starting selegiline treatment. The DATATOP study'5 found statistically significant short-term ("wash-in") benefits that favoured the selegiline-treated patients, but the changes were slight and possibly of no clinical consequence.
Moreover, they could not adequately explain a long-term reduction in the rate of reaching end-point (see below). Neither study has so far detected significant clinical deterioration during the washout period. Nor, with the rating scales used, was any anti-depressant effect of selegiline detected which might have influenced the patients' willingness to soldier on without levodopa. Although the use of multiple analyses always introduces the possibility of freak individually significant results, the effect was fairly consistent across all measures of disability. The smaller California study'4 (27 Unfortunately, its use was commonly associated with nausea, vomiting, hypotension and drowsiness, and the oral preparation caused reversible azotaemia. However, Corsini et al in 197923 showed that the peripheral side-effects could be controlled by oral domperidone. Taking leaves from the diabetologists' book the group at University College/Middlesex Hospital in London24 (and others2128) have since convincingly demonstrated that repeated single subcutaneous injections of apomorphine using a Penject system, and suitably targeted to be given during, or in anticipation of, off periods, significantly reduces daily off time in fluctuating patients. Benefit usually occurs within 5-15 minutes, and lasts 40-90 minutes. More complex cases have been given continuous day-time subcutaneous infusions of apomorphine using a simple battery-operated syringe-driver pump.
The article in this issue29 expands their earlier experience. Of 57 patients accepted for treatment, six failed to gain a worthwhile response. In 30 patients who received 2-18 (mean 4 8) injections/day, each of 0-2 to 5 (mean 2 2) mg, mean daily off time fell from 6-9 to 2-9 hours. In 21 patients receiving continuous daytime infusion, usually at 2 to 4 mg/hr, with an additional mean of 9 5 "on demand" boluses of mean 2-4 mg, mean hours off per day fell from 9 9 to 4 5, and a significant reduction in daily levodopa dosage was possible in most subjects. The effect on dyskinesias was variable: most patients with diphasic dyskinesias fared badly, and even with peak dose chorea it was not always possible to achieve worthwhile improvement.
Another benefit of acute boluses of apomorphine is prompt relief from a number of unpleasant positive off period phenomena, in particular distressing attacks of painful, fixed, off period dystonia.25 The 
